International surveillance of blood stream infections due to Candida species in the European SENTRY program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents

Diagnostic Microbiology and Infectious Disease

Volumn 35, Issue 1, 1999, Pages 19-25

  Pfaller, M A ^a   Jones, R N ^b   Doern, G V ^b   Fluit, A C ^b   Verhoef, J ^b   Sader, H S ^b   Messer, S A ^b   Houston, A ^b   Coffman, S ^b   Hollis, R J ^b  

^a Medical Microbiology Division   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; BLOOD FLOW; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CONTROLLED STUDY; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; EUROPE; FUNGEMIA; HUMANS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; TRIAZOLES;

EID: 0033199604     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00046-2     Document Type: Article

References (26)

1. Abi-Said D., Anaissie E., Uzun Q., Raad I., Pinzcowski H., Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 24:1997;1122-1128.
2. Barry A.L., Brown S.D. In vitro studies of two triazole antifungal agents (voriconazole [UK-109-496] and fluconazole) against Candida species. Antimicrob Agents Chemother. 40:1996;1948-1949.
3. Brunn B., Westh H., Stenderup J. Fungemia An increasing problem in a Danish University Hospital 1989 to 1994 . Clin Microbiol Infect. 1:1995;124-126.
4. Edwards J.E. Jr, Bodey G.P., Bowden R.A., et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis. 25:1997;43-59.
5. Fung-Tomc J.C., Huckzko E., Minassian B., Bonner D.P. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother. 42:1998;313-318.
6. Hajdu R., Thompson R., Sundelof J.G., Pelak B.A., Bouffard F.A., Dropinski J.F., Kropp H. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother. 41:1997;2339-2344.
7. Levin A.S., Costa S.F., Mussi N.S., Basso M., Sinto S.I., Machado C., Geiger D.C., Villares M.C.B., Schreiber A.Z., Boraone A.A., Branchini M.L.M. Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and hands of health care workers. Diagn Microbiol Infect Dis. 30:1998;243-249.
8. Marco F., Pfaller M.A., Messer S., Jones R.N. In vitro activities of voriconazole (UK-109-496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother. 42:1998;161-163.
9. Marco F., Pfaller M.A., Messer S.A., Jones R.N. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis. 31:1998;33-37.
10. National Committee for Clinical Laboratory Standards (1997) Reference methods for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
11. Nguyen M.H., Peacock J.E., Morris A.J., Tanner D.C., Nguyen M.L., Snydman D.R., Wagener M.M., Rinaldi M.G., Yu V.L. The changing face of candidemia Emergence of non-Candida albicans species and antifungal resistance . Am J Med. 100:1996;617-623.
12. Pfaller M.A. Nosocomial candidiasis Emerging species, reservoirs, and modes of transmission . Clin Infect Dis. 22:(suppl 2):1996;S89-S94.
13. Pfaller M.A., Messer S., Jones R.N. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother. 41:1997;233-235.
14. Pfaller M.A., Jones R.N., Messer S.A., Edmond M.B., Wenzel R.P. National surveillance of nosocomial blood stream infections due to species of Candida other than Candida albicans Frequency of occurrence and antifungal susceptibility in the SCOPE Program . Diagn Microbiol Infect Dis. 30:1998;121-129.
15. Pfaller M.A., Messer S.A., Houston A., et al. National Epidemiology of Mycoses Survey A multicenter study of strain variation and antifungal susceptibility among isolates of Candida species . Diagn Microbiol Infect Dis. 31:1998;289-296.
16. Pfaller M.A., Jones R.N., Messer S.A., Edmond M.B., Wenzel R.P. National surveillance of nosocomial blood stream infection due to Candida albicans Frequency of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program . Diagn Microbiol Infect Dis. 31:1998;327-332.
17. Pfaller M.A., Jones R.N., Doern G.V., Sader H.S., Hollis R.J., Messer S.A. International surveillance of blood stream infections due to Candida species Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program . J Clin Microbiol. 36:1998;1886-1889.
18. Rex J.H., Pfaller M.A., Galgiani J.N., Bartlett M.S., Espinel-Ingroff A., Ghannoum M.A., Lancaster M., Rinaldi M.G., Walsh T.J., Barry A.L. Development of interpretive breakpoints for antifungal susceptibility testing Conceptual framework and analysis of in vitro - in vivo correlation data for fluconazole, itraconazole, and Candida infections . Clin Infect Dis. 24:1997;235-247.
19. Ruhnke M., Schmidt-Westhausen A., Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 41:1997;575-577.
20. Sheehan D.J., Hitchcock C.A., Sibley C.M. Current and emerging azole antifungal agents. Clin Microbiol Rev. 12:1999;40-79.
21. Voss A., Kluytmans J.J.A.W., Koleman J.G.M., Spanjaaard L., Vandenbroucke-Grauls C.M.J.E., Verbrugh H.A., Vos M.C., Weerskink A.Y.L., Hoogskamp-Korstanje J.A.A., Meis J.F.G.M. Occurrence of yeast blood stream infections between 1987 and 1995 in five Dutch University Hospitals. Eur J Clin Microbiol Infect Dis. 15:1996;909-912.
22. Warren N.G., Hazen K.C. Candida, Cryptococcus, and other yeasts of medical importance. Murray P.R., Baron E.J., Pfaller M.A., Tenover F.C., Yolken R.H. Manual of Clinical Microbiology. 6th ed. 1995;723-737 American Society for Microbiology, Washington, DC.
23. White T.C., Marr K.A., Bowden R.A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 11:1998;382-402.
24. Wingard J.R. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis. 20:1995;115-125.
25. Wingard J.R., Merz W.G., Rinaldi M.G., Johnson T.R., Karp J.E., Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 325:1991;1274-1277.
26. Wingard J.R., Merz W.G., Rinaldi M.G., Miller C.B., Karp J.E., Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother. 37:1993;1847-1849.